“`html
Medicare Drug Price Negotiations Expand,But Key Cancer drugs Remain Shelved
Table of Contents
- 1. Medicare Drug Price Negotiations Expand,But Key Cancer drugs Remain Shelved
- 2. Which Drugs Are Affected?
- 3. A Broader Impact, But Limited for Some
- 4. What savings can Medicare beneficiaries expect from the 2028 drug price negotiation plan?
- 5. medicare Targets $27 Billion in High-Cost Drugs for 2028 Price Cuts
- 6. Understanding the Drug Selection Process
- 7. Impact on Medicare Beneficiaries
- 8. How Price Negotiation Works
- 9. Pharmaceutical Industry Response & Legal Challenges
- 10. The Role of Biosimilars and Generics
- 11. potential Long-Term Effects
- 12. real-World Example: Impact of Insulin Price caps
- 13. benefits for Specific Conditions
Washington D.C. – The Federal Government announced a new wave of 15 medications slated for price negotiations with Medicare, a move enabled by the Inflation Reduction Act.These negotiations, set to take effect in 2028, aim to lower healthcare costs for millions of Americans and represent a meaningful shift in the pharmaceutical landscape.
Which Drugs Are Affected?
The latest list includes medications addressing a range of conditions, with a notable expansion into drugs administered in doctor’s offices. Key inclusions are the breast cancer treatments Kisqali and Verzenio, the HIV medication Biktarvy, and a selection of drugs for rheumatoid arthritis – Orencia, cimzia, and Xeljanz. Botox, when used therapeutically for conditions like migraines, is also included in this round.
This marks the first time Medicare is extending its negotiating power to drugs under Part B, covering medications administered by healthcare professionals, widening the scope of potential savings. Experts estimate these 15 drugs currently account for approximately $27 billion in Medicare expenditure, impacting around 1.8 million beneficiaries. Eli Lilly’s Trulicity, a popular diabetes treatment, carries the highest annual cost at $4.9 billion.
A Broader Impact, But Limited for Some
Centers for Medicare and Medicaid Services Administrator Mehmet Oz stated the agency is “taking strong action to target the most expensive drugs in Medicare, negotiate fair prices, and make sure the system works for patients.” While the initiative is expected to yield significant savings,analysts suggest that most pharmaceutical companies will see minimal financial impact.
Though, Gilead Sciences could face an 8% reduction in Medicare revenue due to negotiations surrounding Biktarvy, according to recent assessments. The remaining companies involved are projected to experience an impact of 3% or less on their overall revenue.
| Drug name | Condition Treated | Estimated Annual Medicare Cost |
|---|---|---|
| Trulicity | Type 2 Diabetes | $4.9 Billion |
| Kisqali | Breast Cancer | Data Unavailable |
| Verzenio | breast Cancer | Data Unavailable |
| Biktarvy | HIV | Data Unavailable |
Orencia
What savings can Medicare beneficiaries expect from the 2028 drug price negotiation plan?
medicare Targets $27 Billion in High-Cost Drugs for 2028 Price CutsThe Centers for Medicare & Medicaid Services (CMS) has announced plans to negotiate lower prices for a new set of 30 high-expenditure prescription drugs under the Inflation Reduction Act (IRA). This initiative, slated to take effect in 2028, aims to save Medicare beneficiaries and the program itself an estimated $27 billion over the next decade. this represents a significant step towards increasing prescription drug affordability and controlling healthcare costs. Understanding the Drug Selection ProcessThe drugs selected for negotiation aren’t chosen randomly.CMS prioritizes medications with the highest total costs to Medicare, excluding those with generic or biosimilar competition. The initial list, released in September 2023, included blockbuster drugs treating conditions like diabetes, heart disease, and cancer. Here’s a breakdown of the criteria used for selection: * High Medicare Expenditure: drugs accounting for a ample portion of Medicare’s total drug spending. * Lack of Generic Competition: Focus on brand-name drugs without readily available, lower-cost alternatives. * Single Source or Limited Competition: Drugs where a single manufacturer dominates the market. * Years on Market: Drugs that have been on the market for a sufficient period (generally, at least 7 years for small molecule drugs and 11 years for biologics) to allow for price negotiation without stifling innovation. The 2028 negotiation round builds on the first set of drugs selected for price reductions begining in 2026.This phased approach allows CMS to refine the negotiation process and assess its impact. Impact on Medicare BeneficiariesThe anticipated price reductions will directly benefit medicare Part D enrollees. Lower drug prices translate to: * Reduced Out-of-Pocket Costs: Beneficiaries will pay less for their medications at the pharmacy counter. * Lower Premiums: Potential for decreased Part D premiums as overall drug costs for the program decline. * improved Access to Medications: Increased affordability can lead to better adherence to prescribed treatments. * Cap on Out-of-Pocket Spending: The $2,000 Part D out-of-pocket cap, already in effect, will be even more impactful with lower drug prices. How Price Negotiation WorksThe negotiation process is structured and involves several key steps:
Manufacturers who refuse to participate in negotiations face significant financial penalties, including excise taxes and potential exclusion from Medicare and medicaid programs. Pharmaceutical Industry Response & Legal ChallengesThe pharmaceutical industry has strongly opposed the IRA’s drug price negotiation provisions,arguing that it will stifle innovation and reduce investment in research and development. Several pharmaceutical companies and industry groups have filed lawsuits challenging the constitutionality of the law, claiming it violates the Fifth Amendment’s takings clause and due process rights. These legal challenges are ongoing, with rulings expected to shape the future of drug pricing in the United States. The PhRMA (Pharmaceutical Research and Manufacturers of America) has been a leading voice in these legal battles. The Role of Biosimilars and GenericsWhile the IRA focuses on negotiating prices for brand-name drugs, the increased availability of biosimilars and generic drugs plays a crucial role in lowering overall healthcare costs. Biosimilars, which are highly similar to existing biologic drugs, offer a more affordable alternative. Similarly, generic drugs provide cost-effective options for many commonly prescribed medications. CMS actively encourages the use of biosimilars and generics through various initiatives, including educational programs for healthcare providers and beneficiaries. potential Long-Term Effectsthe long-term effects of the IRA’s drug price negotiation provisions are still uncertain. However, potential outcomes include: * Shift in Pharmaceutical R&D: Drug companies may prioritize research and development in areas less likely to be subject to price negotiation. * Increased Focus on Innovation: A potential drive towards developing truly novel therapies with significant clinical advantages. * Greater Transparency in Drug Pricing: Increased scrutiny of drug pricing practices and a push for greater transparency. * Model for Other Countries: The IRA could serve as a model for other countries seeking to control drug costs. real-World Example: Impact of Insulin Price capsPrior to the IRA, the cost of insulin was a major burden for many Medicare beneficiaries with diabetes. The IRA included a $35 monthly cap on insulin costs for those enrolled in Medicare Part D. This cap has provided significant relief to millions of Americans, demonstrating the potential impact of government intervention in drug pricing. This is a clear example of affordable healthcare in action. benefits for Specific ConditionsThe drugs targeted for negotiation address a wide range of health conditions.Beneficiaries with conditions 
Dr. Priya Deshmukh - Senior Editor, Health Warner Bros. Discovery and TikTok Partner to Elevate the 2026 Winter Olympics ExperienceMalaysia’s Football Association Executive Committee Resigns Amid Naturalization Scandal and FIFA Sanctions |